Emzor Pharma Funding SPV Plc has raised ₦26.70 billion through a five-year fixed-rate bond listed on the FMDQ Exchange as the indigenous pharmaceutical company moves to expand its manufacturing capacity and strengthen local drug production. The Series 1 bond, which carries a 19 per cent interest rate, was issued under the company’s ₦40 billion Bond Issuance Programme.
The funds will be used to meet working capital requirements and finance the expansion of Emzor Pharmaceutical Industries Limited’s manufacturing operations. A significant portion of the financing will support the completion of Africa’s first full-scale antimalarial Active Pharmaceutical Ingredient manufacturing plant. The project is expected to increase domestic production of pharmaceutical inputs and reduce Nigeria’s reliance on imported APIs, a key component in the manufacture of medicines.
Emzor Chairman, Emeka Okoli, described the bond as an important step in the company’s drive to expand pharmaceutical manufacturing in Nigeria. He said the strong investor response and oversubscription demonstrated confidence in Emzor’s financial position and growth strategy.
The bond issuance is a significant development for Nigeria’s pharmaceutical industry. The country has long relied on imported pharmaceutical ingredients, and the antimalarial API plant will reduce that dependence. The oversubscription of the bond is a sign of investor confidence in the sector. The 19 per cent interest rate, however, reflects the high cost of capital in Nigeria.
The winners: Emzor, which has secured funding for expansion; and the Nigerian pharmaceutical industry, which gains local manufacturing capacity. The losers: importers of pharmaceutical ingredients, who face competition; and the Nigerian government, which must create an enabling environment for the sector.
Bottom Line: Emzor has raised ₦26.7 billion for drug production. Africa’s first antimalarial API plant is on the way. The question is whether the plant will reduce Nigeria’s dependence on imports.